MCL-1 antagonism enhances the anti-invasive effects of dasatinib in pancreatic adenocarcinoma

Autor: Castillo L, Young AIJ, Mawson A, Schafranek P, Steinmann AM, Nessem D, Parkin A, Johns A, Chou A, Law AMK, Lucas MC, Murphy KJ, Deng N, Gallego-Ortega D, Caldon CE, Australian Pancreatic Cancer Genome Initiative (APGI), Timpson P, Pajic M, Ormandy CJ, Oakes SR

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest malignancies. It is phenotypically heterogeneous with a highly unstable genome and provides few common therapeutic targets. We found that MCL1, Cofilin1 (CFL1) and SRC mRNA were hig

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______363::6c1e7aebf93256bc3fd0ad16986ca325
https://hdl.handle.net/10453/144833

Short-term PI3K Inhibition Prevents Breast Cancer in Preclinical Models.

Autor: Ku AT; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas., Young AIJ; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas., Ibrahim AA; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas., Bu W; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas., Jiang W; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas., Lin M; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas., Williams LC; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas., McCue BL; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas., Miles G; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas., Nagi C; Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas., Behbod F; Pathology and Laboratory Medicine, University of Kansas, Lawrence, Kansas., Li Y; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.

Publikováno v: Cancer prevention research (Philadelphia, Pa.) [Cancer Prev Res (Phila)] 2023 Feb 06; Vol. 16 (2), pp. 65-73.

Tfap2b specifies an embryonic melanocyte stem cell that retains adult multifate potential.

Autor: Brombin A; MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XU, UK; CRUK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XU, UK., Simpson DJ; MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XU, UK., Travnickova J; MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XU, UK; CRUK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XU, UK., Brunsdon H; MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XU, UK; CRUK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XU, UK., Zeng Z; MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XU, UK; CRUK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XU, UK., Lu Y; MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XU, UK; CRUK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XU, UK., Young AIJ; MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XU, UK; CRUK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XU, UK., Chandra T; MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XU, UK. Electronic address: tamir.chandra@ed.ac.uk., Patton EE; MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XU, UK; CRUK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XU, UK. Electronic address: e.patton@ed.ac.uk.

Publikováno v: Cell reports [Cell Rep] 2022 Jan 11; Vol. 38 (2), pp. 110234.

MCL-1 antagonism enhances the anti-invasive effects of dasatinib in pancreatic adenocarcinoma.

Autor: Castillo L; Cancer Research Division, Garvan Institute of Medical Research and the Kinghorn Cancer Centre, 384 Victoria Street, Darlinghurst, NSW, 2010, Australia., Young AIJ; Cancer Research Division, Garvan Institute of Medical Research and the Kinghorn Cancer Centre, 384 Victoria Street, Darlinghurst, NSW, 2010, Australia., Mawson A; Cancer Research Division, Garvan Institute of Medical Research and the Kinghorn Cancer Centre, 384 Victoria Street, Darlinghurst, NSW, 2010, Australia., Schafranek P; Cancer Research Division, Garvan Institute of Medical Research and the Kinghorn Cancer Centre, 384 Victoria Street, Darlinghurst, NSW, 2010, Australia., Steinmann AM; Cancer Research Division, Garvan Institute of Medical Research and the Kinghorn Cancer Centre, 384 Victoria Street, Darlinghurst, NSW, 2010, Australia., Nessem D; Cancer Research Division, Garvan Institute of Medical Research and the Kinghorn Cancer Centre, 384 Victoria Street, Darlinghurst, NSW, 2010, Australia., Parkin A; Cancer Research Division, Garvan Institute of Medical Research and the Kinghorn Cancer Centre, 384 Victoria Street, Darlinghurst, NSW, 2010, Australia., Johns A; Cancer Research Division, Garvan Institute of Medical Research and the Kinghorn Cancer Centre, 384 Victoria Street, Darlinghurst, NSW, 2010, Australia.; St. Vincent's Clinical School, UNSW Medicine, 384 Victoria Street, Kensington, NSW, 2052, Australia., Chou A; University of Sydney, Camperdown, NSW, 2006, Australia., Law AMK; Cancer Research Division, Garvan Institute of Medical Research and the Kinghorn Cancer Centre, 384 Victoria Street, Darlinghurst, NSW, 2010, Australia., Lucas MC; Cancer Research Division, Garvan Institute of Medical Research and the Kinghorn Cancer Centre, 384 Victoria Street, Darlinghurst, NSW, 2010, Australia., Murphy KJ; Cancer Research Division, Garvan Institute of Medical Research and the Kinghorn Cancer Centre, 384 Victoria Street, Darlinghurst, NSW, 2010, Australia., Deng N; Cancer Research Division, Garvan Institute of Medical Research and the Kinghorn Cancer Centre, 384 Victoria Street, Darlinghurst, NSW, 2010, Australia.; St. Vincent's Clinical School, UNSW Medicine, 384 Victoria Street, Kensington, NSW, 2052, Australia., Gallego-Ortega D; Cancer Research Division, Garvan Institute of Medical Research and the Kinghorn Cancer Centre, 384 Victoria Street, Darlinghurst, NSW, 2010, Australia.; St. Vincent's Clinical School, UNSW Medicine, 384 Victoria Street, Kensington, NSW, 2052, Australia., Caldon CE; Cancer Research Division, Garvan Institute of Medical Research and the Kinghorn Cancer Centre, 384 Victoria Street, Darlinghurst, NSW, 2010, Australia.; St. Vincent's Clinical School, UNSW Medicine, 384 Victoria Street, Kensington, NSW, 2052, Australia., Timpson P; Cancer Research Division, Garvan Institute of Medical Research and the Kinghorn Cancer Centre, 384 Victoria Street, Darlinghurst, NSW, 2010, Australia.; St. Vincent's Clinical School, UNSW Medicine, 384 Victoria Street, Kensington, NSW, 2052, Australia., Pajic M; Cancer Research Division, Garvan Institute of Medical Research and the Kinghorn Cancer Centre, 384 Victoria Street, Darlinghurst, NSW, 2010, Australia.; St. Vincent's Clinical School, UNSW Medicine, 384 Victoria Street, Kensington, NSW, 2052, Australia., Ormandy CJ; Cancer Research Division, Garvan Institute of Medical Research and the Kinghorn Cancer Centre, 384 Victoria Street, Darlinghurst, NSW, 2010, Australia.; St. Vincent's Clinical School, UNSW Medicine, 384 Victoria Street, Kensington, NSW, 2052, Australia., Oakes SR; Cancer Research Division, Garvan Institute of Medical Research and the Kinghorn Cancer Centre, 384 Victoria Street, Darlinghurst, NSW, 2010, Australia. s.oakes@garvan.org.au.; St. Vincent's Clinical School, UNSW Medicine, 384 Victoria Street, Kensington, NSW, 2052, Australia. s.oakes@garvan.org.au.

Publikováno v: Oncogene [Oncogene] 2020 Feb; Vol. 39 (8), pp. 1821-1829. Date of Electronic Publication: 2019 Nov 18.

A mutation in the viral sensor 2'-5'-oligoadenylate synthetase 2 causes failure of lactation.

Autor: Oakes SR; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St. Vincent's Clinical School, UNSW Medicine, UNSW Sydney, NSW, Australia., Gallego-Ortega D; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St. Vincent's Clinical School, UNSW Medicine, UNSW Sydney, NSW, Australia., Stanford PM; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia., Junankar S; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St. Vincent's Clinical School, UNSW Medicine, UNSW Sydney, NSW, Australia., Au WWY; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia., Kikhtyak Z; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia., von Korff A; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia., Sergio CM; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia., Law AMK; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia., Castillo LE; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia., Allerdice SL; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia., Young AIJ; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia., Piggin C; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia., Whittle B; Australian Phenomics Facility, The Australian National University, Canberra, ACT, Australia., Bertram E; Australian Phenomics Facility, The Australian National University, Canberra, ACT, Australia., Naylor MJ; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; School of Medical Sciences and Bosch Institute, Sydney Medical School, University of Sydney, Sydney, NSW, Australia., Roden DL; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St. Vincent's Clinical School, UNSW Medicine, UNSW Sydney, NSW, Australia., Donovan J; Department of Molecular Biology, Princeton University, Princeton, New Jersey, United States of America., Korennykh A; Department of Molecular Biology, Princeton University, Princeton, New Jersey, United States of America., Goodnow CC; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St. Vincent's Clinical School, UNSW Medicine, UNSW Sydney, NSW, Australia.; Australian Phenomics Facility, The Australian National University, Canberra, ACT, Australia., O'Bryan MK; The School of Biological Sciences, Monash University, Clayton, Australia., Ormandy CJ; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St. Vincent's Clinical School, UNSW Medicine, UNSW Sydney, NSW, Australia.

Publikováno v: PLoS genetics [PLoS Genet] 2017 Nov 08; Vol. 13 (11), pp. e1007072. Date of Electronic Publication: 2017 Nov 08 (Print Publication: 2017).